Zacks Investment Research cut shares of Cutera (NASDAQ:CUTR) from a strong-buy rating to a hold rating in a research report report published on Wednesday morning.
According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “
A number of other analysts also recently issued reports on the company. Stifel Nicolaus began coverage on Cutera in a research report on Monday. They set a hold rating and a $55.00 price target for the company. BidaskClub upgraded Cutera from a buy rating to a strong-buy rating in a research report on Saturday, April 7th. Stephens began coverage on Cutera in a research report on Tuesday, March 13th. They set an overweight rating and a $60.00 price target for the company. Finally, Gabelli reiterated a buy rating on shares of Cutera in a research report on Friday, February 16th. Three analysts have rated the stock with a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and an average target price of $46.67.
Cutera (NASDAQ:CUTR) last posted its earnings results on Wednesday, February 14th. The medical device company reported $0.42 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.33 by $0.09. The business had revenue of $47.60 million during the quarter, compared to analyst estimates of $43.96 million. Cutera had a return on equity of 18.31% and a net margin of 19.80%. The company’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.30 EPS. equities research analysts expect that Cutera will post 1.1 earnings per share for the current fiscal year.
Several institutional investors and hedge funds have recently modified their holdings of the company. Rehmann Capital Advisory Group bought a new stake in shares of Cutera during the 4th quarter valued at about $222,000. MetLife Investment Advisors LLC bought a new stake in Cutera in the 4th quarter worth approximately $306,000. Municipal Employees Retirement System of Michigan bought a new stake in Cutera in the 4th quarter worth approximately $240,000. Millennium Management LLC bought a new stake in Cutera in the 4th quarter worth approximately $1,305,000. Finally, Ladenburg Thalmann Financial Services Inc. lifted its position in Cutera by 3,400.0% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 3,500 shares of the medical device company’s stock worth $159,000 after buying an additional 3,400 shares during the last quarter. Hedge funds and other institutional investors own 97.19% of the company’s stock.
Cutera Company Profile
Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.